Importantly, treating the primary CLL B cells with cyclosporin A (CsA), a calcineurin inhibitor known to suppress the NFATc1 nuclear localization [40], suppressed APOBEC3 expression (Fig. 4E). The gene discussed is NFATC1; the disease is B-cell chronic lymphocytic leukemia.